J2779 Inj, susvimo 0.1 mg

Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

• Medicare coverage: Carrier judgment
• Status: active (July 2026 file)
• MUE: max 200 units per day (practitioner), rationale: Anatomic Consideration